Prescription for Better Access
With pharmaceutical and biotech manufacturers launching more high-cost specialty drugs and the insurance industry increasing the use of more restricti…
Jul 17th, 2025 |
00:00
The Future of Access, a Live Podcast Recording from the ACCESS US 2025 Conference
At ACCESS US 2025, our live podcast The Future of Access features four experts exploring how to improve drug affordability and access while maintaining innovation. With rising drug costs, we ask: What bold models are emerging? We cover benefit design, PBMs, AI, evolving pharmacy models, and whether markets can act before regulation.
- Conference Overview
- Sarah Emond – ICER
- John O’Brien – National Pharmaceutical Council
- Annette Powers – Bristol Myers Squibb
- Ray Pressburger – Accenture
- Stuart Altman – Power, Politics and Universal Health Care
- PBMs
- 340B Program
- Copay Maximizers
- Net Price
- Lilly Direct
- Indolent Disease, PFS
- Concomitant Drug
- HIV & AZT
- Orphan Drugs
- Calquence vs Imbruvica
- Value-Based Contracts
- Outcome-Based Contracts
- Disruptive PBMs
- CostPlus Drugs
- Fair Access 2024
- Drug Rebates
- Drug Carve-Outs
- Dynamic Pricing
- Accelerated Approvals
- ICER Assessment
Questions? Email comments@prescriptionforbetteraccess.com.
Follow us on X, LinkedIn, YouTube, and Threads.